Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide

Nitin T. Supekar, Vani Lakshminarayanan, Chantelle J. Capicciotti, Anju Sirohiwal, Cathy S. Madsen, Margreet A. Wolfert, Peter A Cohen, Sandra J Gendler, Geert Jan Boons

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A fully synthetic MUC1-based cancer vaccine was designed and chemically synthesized containing an endogenous helper T-epitope (MHC classII epitope). The vaccine elicited robust IgG titers that could neutralize cancer cells by antibody-dependent cell-mediated cytotoxicity (ADCC). It also activated cytotoxic T-lymphocytes. Collectively, the immunological data demonstrate engagement of helper T-cells in immune activation. A synthetic methodology was developed for a penta-glycosylated MUC1 glycopeptide, and antisera of mice immunized by the new vaccine recognized such a structure. Previously reported fully synthetic MUC1-based cancer vaccines that elicited potent immune responses employed exogenous helper T-epitopes derived from microbes. It is the expectation that the use of the newly identified endogenous helper T-epitope will be more attractive, because it will activate cognate CD4+ T-cells that will provide critical tumor-specific help intratumorally during the effector stage of tumor rejection and will aid in the generation of sustained immunological memory.

Original languageEnglish (US)
JournalChemBioChem
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Cancer Vaccines
Glycopeptides
T-cells
Epitopes
Tumors
Vaccines
Immunologic Memory
Antibody-Dependent Cell Cytotoxicity
Neoplasms
Rubiaceae
Cytotoxic T-Lymphocytes
Cytotoxicity
Helper-Inducer T-Lymphocytes
Immune Sera
Immunoglobulin G
Chemical activation
Cells
T-Lymphocytes
Data storage equipment
Antibodies

Keywords

  • Cancer
  • Endogenous helper
  • Glycopeptide
  • Multicomponent vaccine
  • T-epitope

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Organic Chemistry

Cite this

Supekar, N. T., Lakshminarayanan, V., Capicciotti, C. J., Sirohiwal, A., Madsen, C. S., Wolfert, M. A., ... Boons, G. J. (Accepted/In press). Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. ChemBioChem. https://doi.org/10.1002/cbic.201700424

Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. / Supekar, Nitin T.; Lakshminarayanan, Vani; Capicciotti, Chantelle J.; Sirohiwal, Anju; Madsen, Cathy S.; Wolfert, Margreet A.; Cohen, Peter A; Gendler, Sandra J; Boons, Geert Jan.

In: ChemBioChem, 01.01.2017.

Research output: Contribution to journalArticle

Supekar, Nitin T. ; Lakshminarayanan, Vani ; Capicciotti, Chantelle J. ; Sirohiwal, Anju ; Madsen, Cathy S. ; Wolfert, Margreet A. ; Cohen, Peter A ; Gendler, Sandra J ; Boons, Geert Jan. / Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. In: ChemBioChem. 2017.
@article{0669f618fcff4c278bcb54170cdf8d3b,
title = "Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide",
abstract = "A fully synthetic MUC1-based cancer vaccine was designed and chemically synthesized containing an endogenous helper T-epitope (MHC classII epitope). The vaccine elicited robust IgG titers that could neutralize cancer cells by antibody-dependent cell-mediated cytotoxicity (ADCC). It also activated cytotoxic T-lymphocytes. Collectively, the immunological data demonstrate engagement of helper T-cells in immune activation. A synthetic methodology was developed for a penta-glycosylated MUC1 glycopeptide, and antisera of mice immunized by the new vaccine recognized such a structure. Previously reported fully synthetic MUC1-based cancer vaccines that elicited potent immune responses employed exogenous helper T-epitopes derived from microbes. It is the expectation that the use of the newly identified endogenous helper T-epitope will be more attractive, because it will activate cognate CD4+ T-cells that will provide critical tumor-specific help intratumorally during the effector stage of tumor rejection and will aid in the generation of sustained immunological memory.",
keywords = "Cancer, Endogenous helper, Glycopeptide, Multicomponent vaccine, T-epitope",
author = "Supekar, {Nitin T.} and Vani Lakshminarayanan and Capicciotti, {Chantelle J.} and Anju Sirohiwal and Madsen, {Cathy S.} and Wolfert, {Margreet A.} and Cohen, {Peter A} and Gendler, {Sandra J} and Boons, {Geert Jan}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/cbic.201700424",
language = "English (US)",
journal = "ChemBioChem",
issn = "1439-4227",
publisher = "Wiley-VCH Verlag",

}

TY - JOUR

T1 - Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide

AU - Supekar, Nitin T.

AU - Lakshminarayanan, Vani

AU - Capicciotti, Chantelle J.

AU - Sirohiwal, Anju

AU - Madsen, Cathy S.

AU - Wolfert, Margreet A.

AU - Cohen, Peter A

AU - Gendler, Sandra J

AU - Boons, Geert Jan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - A fully synthetic MUC1-based cancer vaccine was designed and chemically synthesized containing an endogenous helper T-epitope (MHC classII epitope). The vaccine elicited robust IgG titers that could neutralize cancer cells by antibody-dependent cell-mediated cytotoxicity (ADCC). It also activated cytotoxic T-lymphocytes. Collectively, the immunological data demonstrate engagement of helper T-cells in immune activation. A synthetic methodology was developed for a penta-glycosylated MUC1 glycopeptide, and antisera of mice immunized by the new vaccine recognized such a structure. Previously reported fully synthetic MUC1-based cancer vaccines that elicited potent immune responses employed exogenous helper T-epitopes derived from microbes. It is the expectation that the use of the newly identified endogenous helper T-epitope will be more attractive, because it will activate cognate CD4+ T-cells that will provide critical tumor-specific help intratumorally during the effector stage of tumor rejection and will aid in the generation of sustained immunological memory.

AB - A fully synthetic MUC1-based cancer vaccine was designed and chemically synthesized containing an endogenous helper T-epitope (MHC classII epitope). The vaccine elicited robust IgG titers that could neutralize cancer cells by antibody-dependent cell-mediated cytotoxicity (ADCC). It also activated cytotoxic T-lymphocytes. Collectively, the immunological data demonstrate engagement of helper T-cells in immune activation. A synthetic methodology was developed for a penta-glycosylated MUC1 glycopeptide, and antisera of mice immunized by the new vaccine recognized such a structure. Previously reported fully synthetic MUC1-based cancer vaccines that elicited potent immune responses employed exogenous helper T-epitopes derived from microbes. It is the expectation that the use of the newly identified endogenous helper T-epitope will be more attractive, because it will activate cognate CD4+ T-cells that will provide critical tumor-specific help intratumorally during the effector stage of tumor rejection and will aid in the generation of sustained immunological memory.

KW - Cancer

KW - Endogenous helper

KW - Glycopeptide

KW - Multicomponent vaccine

KW - T-epitope

UR - http://www.scopus.com/inward/record.url?scp=85036522055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036522055&partnerID=8YFLogxK

U2 - 10.1002/cbic.201700424

DO - 10.1002/cbic.201700424

M3 - Article

C2 - 29120508

AN - SCOPUS:85036522055

JO - ChemBioChem

JF - ChemBioChem

SN - 1439-4227

ER -